Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onabotulinum toxin A - Allergan

Drug Profile

Onabotulinum toxin A - Allergan

Alternative Names: Botox; Botulinum toxin A injectable-Allergan; GSK 1358820; Vistabel; Vistabex

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Allergan; GlaxoSmithKline; Johns Hopkins University; Queens University; Temple University; University of Illinois at Chicago; Wake Forest University School of Medicine
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity; Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dysphonia; Facial wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Muscle pain; Raynaud's disease
  • Phase II Carpal tunnel syndrome; Gastrointestinal disorders; Herpes labialis; Hypertrophy; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia; Prostatitis
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 24 Oct 2019 Launched for lower limb Muscle spasticity excluding spasticity due to cerebral palsy (In adolescents, In children) in USA (IM)
  • 24 Oct 2019 The US FDA approves sBLA for Lower limb muscle spasticity excluding spasticity due to cerebral palsy (In children, In adolesecents) (IM)
  • 03 Oct 2019 Allergan initiates a phase IIb trial for Glabellar lines in USA (NCT04096326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top